tivozanib (AV-951)

Phase 3

Aveo Pharmaceuticals, Inc. (AVEO)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

1 competitor in Advanced Renal Cell Carcinoma

MRKWelireg

Approved

View Full Landscape

Drug Information

Target Indication

Advanced Renal Cell Carcinoma

Clinical Trial

NCT01030783

Last updated: 12/23/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA8/24/2017

Fotivda

Fotivda is indicated for the first line treatment of adult patients with advanced renal cell carcinoma (RCC) and for adult patients who are VEGFR and mTOR pathway inhibitor-naïve following disease progression after one prior treatment with cytokine therapy for advanced RCC. Treatment of advanced renal cell carcinoma.

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

AVEO

Aveo Pharmaceuticals, Inc.

Healthcare•North America•NASDAQ

Related Pipeline

TivozanibPhase 3

Renal Cell Carcinoma

Tivozanib hydrochloridePhase 3

Carcinoma, Renal Cell